Also Read: Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

Sanofi has managed the daunting task faced by managers worldwide: hauling its employees back to the office with minimal fuss. That’s an impressive feat for a company that said last year it was ...

Image credit: Shutterstock / Wirestock Creators. The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia ...

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at ...

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to $1.9B. The French pharmaceutical company will acquire DR-0201, a CD20 ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.

PARIS, France I March 20, 2025 I Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bio’s autoimmune disease treatment, DR-0201, reinforcing its expansion in the biopharmaceutical sector. The French healthcare giant ...

Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion. The French pharmaceutical company on Thursday said it would ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing over $600 million upfront for Dren Bio’s clinical-stage bispecific antibody, with more than $1 billion in ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune ...